WCA
CRSP icon

Windsor Creek Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Windsor Creek Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,000
Closed -$971K – 139
2021
Q2 		$971K Buy
6,000
+1,500
+33% +$182K 0.25% 97
2021
Q1 		$548K Buy
4,500
+1,000
+29% +$151K 0.14% 120
2020
Q4 		$536K Buy
+3,500
New +$414K 0.14% 126
2020
Q3 		– Sell
-5,000
Closed -$367K – 178
2020
Q2 		$367K Sell
5,000
-19,472
-80% -$1.14M 0.12% 119
2020
Q1 		$1.04M Buy
24,472
+19,472
+389% +$1.01M 0.37% 71
2019
Q4 		$305 Buy
+5,000
New +$273K 0.08% 116

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Windsor Creek Advisors's CRSP Position: Q3 2021 in Review

Windsor Creek Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 6,000 shares — an estimated $971K sold.

Windsor Creek Advisors first reported a position in CRSP in Q4 2019 and held it in 6 quarters. The position peaked at $1.04M in Q1 2020. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Windsor Creek Advisors reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Windsor Creek Advisors sold 6,000 CRISPR Therapeutics shares in Q3 2021, an estimated $971K.
  • Windsor Creek Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 6 quarters.
  • Windsor Creek Advisors's CRISPR Therapeutics position peaked at $1.04M in Q1 2020.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Windsor Creek Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.